StreetInsider.com News Articles

Form 8-K Quince Therapeutics, For: May 20

Thu, 21 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260521/26536727.html

Form 8-K Quince Therapeutics, For: May 20

Thu, 21 May 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260521/26536727.html

Form 8-K/A Quince Therapeutics, For: May 17

Mon, 18 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260518/26514175.html

Form 8-K/A Quince Therapeutics, For: May 17

Mon, 18 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260518/26514175.html

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

Quince Therapeutics Inc. (NASDAQ: QNCX) reported data from a phase 2a study of LAM-001, an inhaled formulation of rapamycin, showing improvements in patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The 24-week, open-label trial enrolled 10 patients across four clinical sites. Six patients completed the study, including four with PH-ILD who were receiving stable doses of treprostinil therapy. The company acquired LAM-001 through its acquisition of Orphai Therapeutics.

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

Quince Therapeutics reports phase 2a trial results for LAM-001 in lung disease

Mon, 18 May 2026 10:22:03 -0400

In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD